Clinical Trial

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Study acronym: TREVI-OC-01
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.
Protocol Amendment History 2 changes
notable Trial sites expanded: 125 -> 299 locations 2026-07-22
minor Completion moved earlier: 2030-05-27 -> 2029-12-27 2026-07-22
Trial Details
NCT Number NCT07218809
Lead Sponsor AstraZeneca
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Ventana Medical Systems, Inc
Conditions Epithelial Ovarian Cancer
Enrollment 1,100 participants
Start Date 2025-12-29
Primary Completion 2028-11-17 (estimated)
Study Completion 2029-12-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-21